Illumicell AI builds a portable "lab scanner" and real-time AI platform that analyzes cells and biomarkers in fluid samples within minutes, initially targeting semen diagnostics for male fertility. The company has collected over 400,000 datapoints and generates structured, labeled cell data to enable personalized insights such as lifestyle-linked fertility changes and early decline warnings. Early clinical trials reportedly outperform legacy systems, and the platform is designed to extend beyond semen to fluids like urine and cerebrospinal fluid. The startup plans an FDA submission in 2026 as it advances clinical validation. Founded in 2023 as a Swiss-American company and led by physician and technical co-founders, illumicell AI has been selected by programs including Harvard i-Labs, Creative Destruction Lab, MassChallenge, Techstars, and Keihanna KGAP+. The company raised funding to accelerate development and commercialization of its real-time diagnostics platform.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2025